ҽѧԺÕÅ´¨½ÌÊÚÍŶÓÔÚACS NANOµÈȨÍþÆÚ¿¯°ä·¢¶àÏî³ÁÒª×êÑгɾÍ

½üÆÚ£¬Ò½Ñ§ÔºÕÅ´¨½ÌÊÚÍŶÓÔÚACS NANO£¨IF=17.1£©¡¢AdvancedScience£¨IF=15.1£©¡¢ChineseChemicalLetters£¨IF=9.1£©ÔÓÖ¾£¨¾ùΪÖпÆÔº1ÇøTOPÆÚ¿¯£©°ä·¢¶àÏî³ÁÒª×êÑгɾÍ¡£

Ò»¡¢ÉúÎï»îÐÔîæÄÉÃ×ø¶Ô×¼ÔÙ¹àעΣÏÕÖеÄÏßÁ£ÌåÒ½ÖÎȱѪÐÔÄÔ×äÖÐ

ÕÅ´¨½ÌÊÚÍŶÓÔÚÃÀ¹ú»¯Ñ§»áÄÉÃ׿ÆѧÁìÓòÆì½¢ÆÚ¿¯ACS NANO£¨ÖпÆÔºÒ»ÇøTOPÆÚ¿¯£¬IF=17.1£©°ä·¢ÁËÌâΪBioactive CeriaNanoenzymesTarget Mitochondria in Reperfusion Injury to Treat Ischemic StrokeµÄ×êÑÐÂÛÎÄ¡£

ȱѪÐÔÄÔ×äÖÐÓµÓиߵķ¢²¡ÂÊ¡¢éæÃüÂʺÍÖ²ÐÂÊ¡¢ÑϸñµÄÒ½Öι¦·ò´°ºÍ°º¹óµÄÒ½ÁÆÓöȡ¢Éç»áÖ°ÊصȷçÏÕ£¬ÒѳÉΪӰÏìÈËÀཡȫµÄËÀÒò£¬Ëæ×Å×êÑеÄÉî¿Ì£¬ÏÖÒÑ´³Õ·ÊÓˮƽÉÏÈÏÖªÁËÑõ×ÔÓÉ»ù¹ýÁ¿ÒýÆðµÄÑõ»¯Ó¦¼¤ÊÇȱѪÐÔÄÔ×äÖеÄÖ÷ÌⲡÀí»·½Ú£¬´óÄÔȱѪȱÑõʱ£¬¹ý¶àµÄÑõ×ÔÓÉ»ù¹¥»÷DNA¡¢RNAºÍµ°°×ÖʵÈ£¬ÃâÒßϸ°û½þÈó£¬ÓÕµ¼ÏßÁ£Ìå·¢³öϸ°ûÔçÆÚµòÍöÒò×Ó£¬´Ó¶øΣÏÕÉñ¾­Ôª¡£ÆäÖÐÏßÁ£Ìå×÷ΪROSµÄ¹Ø¼ü²úÉúµØλ£¬¶ÔÑõ»¯Ó¦¼¤ºÍϸ°ûµòÍö¶¼ÓÐ׏ؼü×÷ÓÃ¡£Òò¶øʹÓðÐÏòÏßÁ£ÌåµÄÕ½Êõµ÷¿ØÏßÁ£Ìå΢»·¾³ÒÔ·øÉäÕû¸öȱѪ΢»·¾³ÊÇÒ½ÖÎÄÔ×äÖеijÁÒªÕ½Êõ¡£

¸Ã×êÑÐÕë¶ÔȱѪÐÔÄÔ×äÖÐÑõ»¯Ó¦¼¤Î¢»·¾³ºÍÑ×֢΢»·¾³¡£Ìá³öÁËÕë¶ÔȱѪÐÔÄÔ×äÖеġ°ÏßÁ£Ìå΢»·¾³µ÷¿Ø¡±ÀíÏë£¬Éè¼ÆºÍ¹¹½¨ÁËÏßÁ£Ìå°ÐÏòµÄÑõ»¯îæÔØÒ©ÄÉÃ×øµÝËÍϵͳ£¬¶ÔËüÃǵÄÉúÎï»îÐÔ¡¢ÌåÄÚ±íҩЧѧºÍ×÷ÓûúÔì½øÐÐÁËÈ«Ãæ¶øϵͳ×êÑÐ£¬Í¨¹ýºÏÀíµÄ¡°ÏßÁ£Ìå΢»·¾³³ÁËÜ¡±Õ½Êõ¼ä½Óµ÷¿ØȱѪ΢»·¾³ÒÔÆÚ»ñµÃ×î¼ÑµÄÒ½ÖγÉЧ£¬²¢Ë÷ÇóÆä¿ÉÄÜ»úÔì£¬½«ÓÐÀûÓÚÍ»ÆÆÏÖÓеÄÒ½ÖÎÆ¿¾±£¬ÎªÈ±ÑªÐÔÄÔ×äÖеݲȫÓÐЧҽÖÎÌṩеÄ˼·¡£

¸Ã×êÑеõ½¹ú¶È³Á´óÐÂÒ©´´ÔìרÏîºÍ¹ú¶ÈÌìÈ»¿Æѧ»ù½ðÒÔ¼°ÉϺ£ÊÐÌìÈ»¿Æѧ»ù½ðµÄÔÞÖú¡£Ð±¦GGΪ±¾ÂÛÎĵÚÒ»ÊðÃûµ¥Ôª£¬Ð±¦GGҽѧԺ˶ʿÉúÁξþºÍ²©Ê¿ÉúÀõÒâΪ¸ÃÂÛÎĵĹ²Í¬µÚÒ»×÷Õß£¬Ð±¦GGÕÅ´¨½ÌÊÚ¡¢ÍõÍ¥·¼¸±×êÑÐÔ±£¬ÉϺ£¿Æ¼¼´óѧÂíÖÇì¿×êÑÐÔ±ºÍˮʦ¾üÒ½´óѧ³Ө½ÌÊÚΪ¸ÃÎĹ²Í¬Í¨Ñ¶×÷Õß¡£

ÂÛÎÄÁ´½Ó£ºhttps://doi.org/10.1021/acsnano.3c10982

¶þ¡¢ÄÉÃ×Á£×ӽ鵼¶¯ÂöÖàÑùÓ²»¯µÄ²¡Àí»úÔì¼°°ÐÏòÒ½ÖÎÕ½Êõ

ÕÅ´¨½ÌÊÚÍŶÓÔÚ×ÛºÏÆÚ¿¯Advanced Science(ÖпÆÔºÒ»ÇøTOPÆÚ¿¯£¬IF 15.1)ÉÏ°ä·¢ÁËÌâΪ¡°Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations¡±µÄ×êÑÐ×ÛÊöÂÛÎÄ¡£

ƾ¾ÝÃÀ¹ú¹úÁ¢ÎÀÉú×êÑÐÔºµÄÊý¾Ý£¬¶¯ÂöÖàÑùÓ²»¯£¨AS£©Ã¿Äêµ¼ÖµÄÈ«ÇòéæÃüÈËÊýԼΪ1760Íò£¬Ê¹Æä³ÉΪȫÇòéæÃüµÄÖØÒªÔ­Òò¡£¶¯ÂöÖàÑùÓ²»¯µÄ²¡Àí»·¾³ÒÔÑ×Ö¢ºÍÖдó¶¯ÂöÖи»º¬Ö¬ÖÊ°ß¿éµÄÐγÉΪÌصã¡£Ä¿Ç°£¬¿¹ÑªÓ×°å¡¢½µÑªÖ¬ºÍѪ¹ÜÊæÕÅÒ©ÎïÖØÒªÓÃÓÚ¶¯ÂöÖàÑùÓ²»¯µÄÁÙ´²Ò½ÖÎ¡£Ò©ÎïÒ½ÖοÉÓÐЧ½ÚÔ춯ÂöÖàÑùÓ²»¯µÄ½øÕ¹;È»¶ø£¬ÓÉÓÚÉúÎïÀûÓöȲîºÍ·ÇÌØÒìÐÔÉ¢²¼µÈ³É·Ö£¬¿Ú·þÒ©ÎïµÄʹÓò¢Ã»ÓлñµÃÁîÈËÖÐÒâµÄÒ½ÖγÉЧ¡£ÎªÁË¿Ë·þ¶¯ÂöÖàÑùÓ²»¯µÄÒ½ÖÎÆ¿¾±£¬È·¶¨ÓÐЧµÄÒ½ÖÎÕ½ÊõºÍÒ©ÎïÖÁ¹Ø³ÁÒª¡£

¸Ã×êÑÐ×ÛÊö¶Ô¶¯ÂöÖàÑùÓ²»¯µÄ²¡Àí»úÔì£¬ÄÉÃ׿ÅÁ£½éµ¼µÄÒ½ÖÎÕ½Êõ£¬ÒÔ¼°½«À´ÄÉÃ×µÝË͵ÄDZÔÚÒ½Öΰеã½øÐÐÁËϵͳ×ܽá¡£½ÒʾÁËÄÉÃ׿ÅÁ£ÓÃÓÚ¶¯ÂöÖàÑùÓ²»¯Ò½ÖεÄDZÁ¦ºÍÌôÕ½£¬²¢Ç¿µ÷ÁËеÄÓÐЧµÄÉè¼Æ˼·¡£

б¦GGΪ±¾ÂÛÎĵÚÒ»ÊðÃûµ¥Ôª£¬Ð±¦GGҽѧԺ˶ʿÉúФ־³Ì¡¢²©Ê¿ÉúÀõÒâºÍÇàÀÏ´óʦÐÜÀñÑàΪ±¾ÎĹ²Í¬µÚÒ»×÷Õß£¬Ð±¦GGҽѧԺÕÅ´¨½ÌÊÚ¡¢ÍõÍ¥·¼¸±×êÑÐÔ±£¬ÖйúÈËÃñ½â·Å¾üÁªÇÚ±£ÏÕ¶ÓÁеھÅÆß©–Ò½ÔºÍþº£Ò½ÁÆÇøÓà´óº£Ö÷ÈκÍÃÀ¹úÊ¥Ô¼º²´óѧ³ÂÕÜÉú½ÌÊÚΪ±¾ÎĹ²Í¬Í¨Ñ¶×÷Õß¡£

ÎÄÕÂÁ´½Ó£ºhttps://onlinelibrary.wiley.com/doi/10.1002/advs.202302918

Èý¡¢»ùÓÚȱѪÐÔÄÔ×äÖÐÉñ¾­±£»¤µÄÏȽøÄÉÃ×µÝËÍϵͳ

ÕÅ´¨½ÌÊÚÍŶÓÔÚÖйú»¯Ñ§»áºÍÖйúҽѧ¿ÆѧԺҩÎï×êÑÐËù½áºÏÖ÷°ì£¬Öйú»¯Ñ§ÁìÓòΨһµÄ¿ì±¨ÀàÆÚ¿¯ChineseChemicalLetters(ÖпÆÔºÒ»ÇøTOPÆÚ¿¯£¬IF9.1)ÔÓÖ¾ÉÏ°ä·¢ÁËÌâΪAdvanced nano drug delivery systems for neuroprotection against ischemic stroke×êÑÐ×ÛÊöÂÛÎÄ¡£¸ÃÎÄΪÕÅ´¨½ÌÊÚÍŶÓ2023ÄêÔÚÒ©¼ÁѧÁìÓò¹ú¼Ê³ÛÃûÆÚ¿¯¡¶Journal of Controlled release¡·ÉÏ°ä·¢·ÂÉúÄÉÃ×µÝËÍϵͳÔÚÄÔ²¿¼²²¡µÄÀûÓýøÕ¹ÂÛÎĺó£¬ÔÚȱѪÐÔÄÔ×äÖÐÁìÓòÓÖÒ»×îнøÕ¹¡£

ȱѪÐÔÄÔ×äÖÐéæÃüÂʺÍÖ²ÐÂÊÉý¸ß£¬¶Ô´óÄÔ½¡È«×é³ÉÁ˳Á´óÍþв¡£Ó×·Ö×ÓÉñ¾­±£»¤¼ÁµÄÁÆЧһÏòÊܵ½´©Ô½ÑªÄÔ·®À飨BBB£©µÄÌôÕ½ºÍÓÐÏÞµÄÉúÎïÀûÓöȵĹÊÕÏ¡£ÎªÁËÌá¸ßÉñ¾­±£»¤¼ÁÔÚÄÔÄÚµÄÓÐЧŨ¶È¡¢¸ÄÉÆÆäÄÔ°ÐÏòµÝËͲ¢½ÚÔìÒ©Î￪ÊÍ£¬Éñ¾­±£»¤ÐÔÄÉÃ׿ÅÁ£Òѱ»Éè¼ÆΪһÖÖÔ¶¾°ÁÉÀ«µÄµÝËÍϵͳ£¬ÓÐÍû¸ÄÉÆISµÄÁÆЧ¡£¸Ã×ÛÊöÖ¼ÔÚ̽ÇóÏȽøµÄÉñ¾­±£»¤ÐÔÄÉÃ׸øҩϵͳ£¬½«Æä×÷ΪÔÚÒ½ÖÎȱѪÐÔÄÔ×äÖеĹý³ÌÖÐʹÓÃÒ©Îï²½ÖèÏò´óÄÔÓÐЧʩÓÃÉñ¾­±£»¤¼ÁµÄÒ»ÖÖ¼¿Á©¡£Í¨¹ý×êÑÐÕâЩϵͳ£¬×êÑÐÈËÔ±ºÍÁÙ´²Ò½ÉúÄܹ»»ñµÃÓмÛÖµµÄ¼û½âºÍ´´Ð¸ÅÏë£¬ËµÃ÷ÏȽøµÄÉñ¾­±£»¤ÐÔÄÉÃ׸øҩϵͳµÄDZÁ¦¡£ÀûÓÃÕâЩ½øÕ¹Äܹ»Íƶ¯¿ª´´ÐԵġ¢ÓÐЧµÄȱѪÐÔÄÔ×äÖÐÒ½ÖιýÎÊ´ëÊ©µÄ½øÕ¹¡£

¸Ã×êÑÐ×ÛÊöÉî¿Ì̽ÇóÁËÏȽøµÄÉñ¾­±£»¤ÐÔ¸øҩϵͳ£¬ÒÔ¿Ë·þ½«Éñ¾­±£»¤¼ÁÊäË͵½´óÄÔÓÃÓÚISÒ½ÖεľÖÏÞÐÔ¡£»¹Ì½ÇóÁËÈôºÎÀûÓÃÔìÒ©²½Öè¼ÓÇ¿Ïò´óÄÔÊäËÍÉñ¾­±£»¤¼Á£¬²¢Ç¿µ÷ÁËÏȽø¸øҩϵͳµÄ×÷ÓÃ¡£Í¨¹ýÏàʶºÍÀûÓÃÕâЩ´´Ð¸øҩϵͳµÄÄÜÁ¦£¬Äܹ»¿ª·¢³öÒ½ÖÎISµÄÐÂÕ½Êõ¡£ÕâЩϵͳӵÓÐÓÅ»¯¸øÒ©·½Ê½¡¢Ìá¸ßÉúÎïÀûÓöȺͼÓÇ¿Éñ¾­±£»¤¼ÁÒ½ÖÎISµÄÁÆЧµÄDZÁ¦¡£¸Ã×ÛÊö½«³Áµã»áÉÌ»ùÓÚÉñ¾­±£»¤¼ÁµÄADDSsÔÚISÒ½ÖÎÖеÄÀûÓÃ¡£´Ë±í£¬»¹»áÉÌÁË»ùÓÚÉñ¾­±£»¤¼ÁµÄÏȽøÒ©ÎïµÝÊÍϵͳÔÚÁÙ´²×êÑÐÖÐÀûÓõÄDZÁ¦ºÍÌôÕ½£¬Ö¼ÔÚΪISÉñ¾­±£»¤Ò½ÖÎÌṩÐÂ˼·ºÍÐÂÊÓ½Ç¡£

б¦GGΪ±¾ÂÛÎĵÚÒ»ÊðÃûµ¥Ôª£¬Ð±¦GGҽѧԺ˶ʿÉúл³½³½£¬ÁξþºÍÉϺ£½»Í¨´óѧҽѧԺ´ÓÊô¹ú¼Ê¸¾Ó×±£½¡Ò½ÔºÕÅÄþΪ±¾ÎĹ²Í¬µÚÒ»×÷Õß£¬Ð±¦GGҽѧԺÕÅ´¨½ÌÊÚ¡¢ÍõÍ¥·¼¸±×êÑÐÔ±£¬Ë®Ê¦¾üÒ½´óѧ³Ө½ÌÊÚºÍÉϺ£½»Í¨´óѧҽѧԺ´ÓÊô¹ú¼Ê¸¾Ó×±£½¡Ò½ÔºÕÅÏþÇì½ÌÊÚΪ±¾ÎĹ²Í¬Í¨Ñ¶×÷Õß¡£

ÎÄÕÂÁ´½Ó£ºhttps://doi.org/10.1016/j.cclet.2023.109149